Lawyers for Leiomyosarcoma (LMS) Cancer Following Hysterectomy, Uterine Fibroid Removal Surgery
The product liability lawyers at Saiontz & Kirk, P.A. are reviewing whether financial compensation may be available through a morcellation lawsuit for women diagnosed with with advanced stage leiomyosarcoma or the spread of other uterine cancer following a minimally invasive, laparoscopic hysterecomy or uterine fibroid removal surgery.
Power morcellators are medical devices that have become increasingly popular in treatment of uterine fibroid tumors, allowing the doctors to cut up the tumor or uterus and remove the tissue through a smaller incision, which reduces recovery time and the risk of infections or other complications.
A small percentage of women undergoing these procedures may actually have undiagnosed sarcoma, which doctors are unable to detect prior to the hysterectomy or myomectomy. A potential side effect of uterine fibroid morcellation for these women, which has not been adequately disclosed, is the risk that the morcellator may cause the spread of cancerous tissue throughout the abdomen and pelvis.
Potential lawsuits are being reviewed by our morcellation cancer lawyers for women throughout the United States who have been diagnosed with leiomyosarcoma (LMS), endometrial stromal sarcoma or other uterine cancer diagnosed following a:
- Laparoscopic Supracervical Hysterectomy
- Robotic Hysterectomy
- Laparoscopic Myomectomy (Uterine Fibroid Removal)
To review whether you, a friend or loved one may be eligible to pursue a morcellator case or wrongful death lawsuit, request a free consultation and claim evaluation.
Power Morcellator Spreading Cancer
The first power morcellator was approved by the FDA in 1995, but the devices have grown in popularity in recent years for uterine fibroid removal or hysterectomy procedures for women with suspected uterine fibroids.
Morcellation involves the use of a bladed tube that is inserted into the abdomen through a small incision. The device then cuts or grinds up parts of the uterus, like uterine fibroids, or the entire uterus in the case of hysterectomies. This tissue is then removed through the port incision, resulting in a minimally invasive procedure.
Reports suggest that about 1 out of every 350 women who undergo a hysterectomy or myomectomy with morcellation may have an unsuspected sarcoma, which doctors are unable to reliable predict prior to the surgery.
During the morcellation surgery, that cancerous tissue may be spread throughout the abdomen and pelvis, causing the diagnosis of aggressive cancer that may have been contained if the morcellator had not been used.
In recent years, concerns have been building among patients and within the medical community, leading the FDA to issue the first warnings about the potential morcellation cancer risk in April 2014, when the U.S. regulatory agency urged doctors to avoid using morcillators during uterine fibroid treatments.
Although many critics have called for a power morcellator recall to be issued, removing the devices from the market entirely, the FDA announced in November 2014 that “black box” warnings will be placed on the devices to ensure doctors adequately review the risk of uterine cancer with patients prior to considering user of the device.
It appears that manufacturers of these medical devices knew or should have known about the unreasonable risk associated with morcellation during a hysterectomy or uterine fibroid removal surgery, yet they withheld information from the medical community and failed to take steps to ensure that their products were safe.
Power morcellators used during procedures in recent years may include, among others:
- Ethicon Gynecare Morcellex
- Blue Endo MoreSolution Tissue Morcellator
- Karl Storz Rotocut G1 Morcellator
Morcellation Class Action Lawyers
The lawyers at Saiontz & Kirk, P.A. are reviewing individual cancer lawsuits and morcellation class action lawsuits for women who have undergone this procedure and been diagnosed with the spread of:
- Endometrial Stromal Sarcoma
- Other Uterine Cancers
Although safer alternatives for uterine fibroid tumor treatment are available, manufacturers of morcellators withheld important information from consumers and the medical community, which may have caused thousands of women to suffer advanced cancer, greatly reducing the length of their life and overall quality of their health.
To review whether you, a friend or family member may have undergone morcellation during a laparoscopic hysterectomy, robotic hysterectomy or laparascopic myomectomy, request a free consultation and claim evaluation with Saiontz & Kirk, P.A.
All cases are reviewed under a contingency fee agreement, which means that there are never any out of pocket expenses associated with hiring our morcellation cancer lawyers. Attorney fees and expenses are only paid if a recovery is obtained.